Envestnet Asset Management Inc Checkpoint Therapeutics, Inc. Transaction History

Envestnet Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$1.02 - $10.6 $25,072 - $260,558	24,581 Added 34.49%	95,841 $100,000
Q2 2022 Aug 03, 2022	SELL	$0.97 - $1.77 $6,343 - $11,575	-6,540 Reduced 8.41%	71,260 $73,000
Q1 2022 May 04, 2022	BUY	$1.53 - $3.25 $16,758 - $35,597	10,953 Added 16.39%	77,800 $138,000
Q4 2021 Feb 04, 2022	BUY	$2.68 - $4.46 $19,239 - $32,018	7,179 Added 12.03%	66,847 $208,000
Q3 2021 Oct 07, 2021	BUY	$2.5 - $3.53 $108,470 - $153,159	43,388 Added 266.51%	59,668 $197,000
Q2 2021 Aug 04, 2021	BUY	$2.36 - $3.2 $10,089 - $13,680	4,275 Added 35.61%	16,280 $48,000
Q1 2021 May 04, 2021	BUY	$2.6 - $4.16 $423 - $678	163 Added 1.38%	12,005 $38,000
Q4 2020 Feb 02, 2021	BUY	$2.19 - $2.96 $25,933 - $35,052	11,842 New	11,842 $31,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.